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Available online 7 April 2016Background: In the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-grade
prostate cancer and significantly reduced the incidence of prostate cancer in men treated with finasteride
compared with placebo. However, an apparent increase in high-grade disease was also observed
among men randomized to finasteride. We aimed to determine why and hypothesized that there is a
grade-dependent response to finasteride.
Methods: From 2007 to 2012, we randomized dynamically by intranet-accessible software 183 men with
localized prostate cancer to receive 5 mg finasteride or placebo daily in a double-blind study during the
4–6 weeks preceding prostatectomy. As the primary end point, the expression of a predefined molecular signa-
ture (ERβ, UBE2C, SRD5A2, and VEGF) differentiating high- and low-grade tumors in Gleason grade (GG) 3 areas
of finasteride-exposed tumors from those in GG3 areas of placebo-exposed tumors, adjusted for Gleason score
(GS) at prostatectomy, was compared. We also determined androgen receptor (AR) levels, Ki-67, and cleaved
caspase 3 to evaluate the effects of finasteride on the expression of its downstream target, cell proliferation,
and apoptosis, respectively. The expression of these markers was also compared across grades between and
within treatment groups. Logistic regression was used to assess the expression of markers.
Findings:We found that the predetermined molecular signature did not distinguish GG3 from GG4 areas in the
placebo group. However, AR expression was significantly lower in the GG4 areas of the finasteride group than
in those of the placebo group. Within the finasteride group, AR expression was also lower in GG4 than in GG3
areas, but not significantly. Expression of cleaved caspase 3 was significantly increased in both GG3 and GG4
areas in the finasteride group compared to the placebo group, although it was lower in GG4 than in GG3 areas
in both groups.Keywords:
Prostate cancer
5α-reductase inhibitors
Finasteride
Cancer prevention
Biomarkerstor; PCPT, Prostate Cancer Prevention Trial; REDUCE, Reduction byDutasteride of Prostate Cancer Events; REDEEM, Reduction by
nagement; DHT, dihydrotestosterone; CRFs, case report forms; DCP, Division of Cancer Prevention; HE, hematoxylin and eosin;
enzyme E2C; SRD5A2, 3-oxo-5α-steroid 4-dehydrogenase 2; VEGF, vascular epithelial growth factor; GS, Gleason score; PZ,
al Institutes of Health (N01-CN-35159). ClinicalTrials.gov trial registration ID: NCT00438464.
ry Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
86 J. Kim et al. / EBioMedicine 7 (2016) 85–93Interpretation:We showed that finasteride's effect on apoptosis and AR expression is tumor grade dependent
after short-term intervention. Thismay explain finasteride's selective suppression of low-grade tumors observed
in the PCPT.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Progress in understanding the biology of advanced prostate cancer
prompted development of therapy for castration-resistant disease;
however, no parallel advances have brought improvement to preven-
tion or treatment of early prostate cancer. This limitation, reflected in
the difficulty in interpreting findings of the Prostate Cancer Prevention
Trial (PCPT) (Thompson et al., 2003) and the Reduction by Dutasteride
of Prostate Cancer Events (REDUCE) trial (Andriole et al., 2010),
led to denial of approval of 5α-reductase inhibitors as prostate cancer
preventatives, despite their striking reduction of low-grade cancers. In
both studies, the 5α-reductase inhibitors reduced the frequency of
low-grade cancers but not potentially lethal high-grade cancers,
pointing to the urgent need to elucidate the biologic significance.
Androgen signaling is central to prostate cancer development and
progression. A milestone in progression of advanced prostate cancer
when it transitions from endocrine-driven to paracrine- or intracrine-
driven androgen signaling, with progressive complexities in steroid
hormone biosynthesis and alterations of the androgen receptor (AR)
(Logothetis et al., 2013). The PCPT, the first study to demonstrate that
prostate cancer could be prevented or greatly delayed (Thompson
et al., 2003), showed that men taking the type 2 5α-reductase steroid
inhibitor finasteride had a relative reduction of 24.8% (P b 0.001) in
the 7-year period prevalence of prostate cancer compared with men
taking the placebo, a reduction that increased to 30% on assessment of
all men who were randomized (Thompson et al., 2013). Paradoxically,
incidence of high-grade disease also significantly increased among
men on finasteride. Although detection bias appeared, in part, to ac-
count for the increase in high-grade disease (Lucia et al., 2007), true
induction of de novo high-grade disease could not be ruled out and,
therefore, the drug was not granted FDA approval for prostate cancer
risk reduction.
The controversy notwithstanding, the PCPT's relevance was made
clear in the Reduction by Dutasteride of Clinical Progression Events in
Expectant Management (REDEEM) trial (Fleshner et al., 2012). In that
study, 302 men with low-grade prostate cancer undergoing active
surveillance received three years of treatment with dutasteride or
placebo. Dutasteride was associated with a 38% decrease in the cancer
detection rate on repeat biopsy at year 3 (Fleshner et al., 2012),
supporting the hypothesis that, based on response to a 5α-reductase
steroid inhibitor, localized prostate cancer could be dichotomized as
either dependent on dihydrotestosterone (DHT) or as able to adapt to
DHT depletion.
To improve biologic understanding of the grade effects offinasteride,
we undertook a randomized controlled trial of short-term finasteride
exposure in men with clinically organ-confined prostate cancer who
were scheduled for prostatectomy. We hypothesized that, following a
short course of finasteride and preceding detectable morphologic
changes, molecular changes associated with high-grade disease would
be apparent.
2. Materials and Methods
2.1. Study Design
We performed a randomized, double-blind, placebo-controlled
parallel trial comparing the tissue effects of 5-mg finasteride with
those of matching placebo given orally daily 4–6 weeks before prosta-
tectomy in patients with clinically organ-confined prostate cancerallocated 1:1 to each group at four academic medical centers. This
study is a window-of-opportunity trial, which takes advantage of the
interval between a clinic visit and admission to the hospital for prosta-
tectomy, for short-term exposure to the study drug. Approved by the
institutional review boards of participating sites and the National
Cancer Institute Division of Cancer Prevention (DCP) Protocol and Safe-
ty Review Committee, the study was led by The University of Texas MD
Anderson Cancer Center Phase I/Phase II Chemoprevention Trials
Consortium inHouston. After a reviewof the purpose, risks, and benefits
of the study, all participants signed and received a copy of a written
consent. The lead organization's institutional review board provided
oversight. Other participating academic centers were Cleveland Clinic
in Cleveland, Ohio, The University of Texas Southwestern Medical
School in Dallas, and The University of Texas Health Science Center at
San Antonio. All sites collected data using protocol-specific case
report forms (CRFs), which were developed from the standard set of
DCP Chemoprevention CRF templates utilizing the National Cancer
Institute – approved Common Data Elements. Also, all sites reported
clinical data using the DCP Oracle clinical remote data capture Web-
based application managed by DCP's monitoring contractor (see
detailed study information at: https://clinicaltrials.gov/ct2/show/
NCT00438464?term=finasteride&rank=8).
2.2. Study Participants
The Pocock-Simon Minimization Method (Pocock & Simon, 1975),
a dynamic randomization method, was used to randomize patients
and stratify them by biopsy GS (6 versus 7), type of prostatectomy
(open vs. laparoscopic/robotic), and study site. Developed at the lead
organization and available by intranet, a software program organized
the randomization of participants and the dispensing of the study
drug at the initial clinical evaluation. Neither patients nor medical staff
members were aware of assignment, and placebo and finasteride pills
were matched in appearance.
Eligible patients had histologic proof of clinically organ-confined
adenocarcinoma of the prostate, clinical stage T1c or T2 disease with
GS 6(3 + 3) or 7(3 + 4) or 7(4 + 3), and a prostate-specific antigen
(PSA) value b10 ng/mL before registration. Participants agreed
while on study not to take dehydroepiandrosterone, phytoestrogen
supplements, antiandrogen therapy, saw palmetto, or dutasteride or
finasteride pills independent of those provided by the study. They also
had to have an Eastern Cooperative Oncology Group performance status
of ≤2, be scheduled for prostatectomy in 4–6 weeks, and agree to
use adequate contraception before and throughout the study. Exclusion
criteria included active malignancy at any other site; prior radiation
therapy for the primary tumor; history of allergic reactions attribut-
ed to compounds of chemical or biologic composition similar
to that of finasteride; uncontrolled intercurrent illness; use of
anticoagulation agents, except for cardioprotective doses of aspirin;
use of all hormonal agents, including testosterone, saw palmetto,
dutasteride, or finasteride six months before study entry (see
detailed study information at: https://clinicaltrials.gov/ct2/show/
NCT00438464?term=finasteride&rank=8).
Primary and secondary end points were prespecified and were
assessed after prostatectomy. The primary end point was to compare
the frequency of the expression of the predetermined molecular signa-
ture (ERβ, UBE2C, SRD5A2, and VEGF) differentiating high- and low-
grade tumors in the GG3 areas of the two study groups, adjusted for
GS at prostatectomy. The secondary end points were to compare the
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specimens in the two study groups, and to compare the frequency of the
expression of the predetermined molecular signature in the GG4 areas
of the two study groups, adjusted for GS at prostatectomy. We also
comparedAR levels, Ki-67, and cleaved caspase 3 across grades between
and within treatment groups.
2.3. Clinical Intervention
Patients were randomly assigned to take a 5-mg finasteride tablet or
matching placebo by mouth daily for 4–6 weeks until admitted for
prostatectomy. Adherence to the regimen was evaluated by pill diary
and a count of leftover tablets.
2.4. Specimen Interrogation
2.4.1. Laboratory Investigation
PSA, testosterone, DHT, estrone, and estradiol levels were measured
at baseline and 24–96 h before prostatectomy. The blood specimens
were processed per a standard operating procedure (Supplementary
Methods S1). Within 24 h of collection, investigators froze and shipped
specimens to the lead organization according to guidelines outlined in
the International Air Transport AssociationDangerous Goods Regulations
(International Air Transport Association, 2006). Levels were measured
by Quest Diagnostics.
2.4.2. Pathology
Pathologists from the four institutions were blinded to treatment
and agreed prospectively on standard operating procedures for
handling prostatectomy specimens (Supplementary Methods S2) and
processing tissue specimens (Supplementary Methods S3). In brief,
prostatectomy specimens were received in ice from the operating
room. Three sets of tissues by the following biopsy schemewere collect-
ed (for future research): sextant biopsy specimens from the posterior
surface, left and right transition zone, one core from each from the
anterior surface, and palpable nodules, if present (Supplementary
Methods S2). One set was placed in formalin and processed to paraffin;
another was placed in RNAase for 24 h at room temperature and then
embedded and frozen in OCT; and a third set was frozen in OCT and
archived at−80 °C. After biopsy cores were collected, the prostatecto-
my specimen was inked, placed in 10% neutral buffered formalin,
fixed for aminimum of two days, and grossed for patient care histologic
procedures and diagnostics.
2.4.3. Immunohistochemistry
Sections of formalin-fixed paraffin-embedded prostatectomy
specimens stained with hematoxylin and eosin (HE) prospectively
collected were reviewed. In order to minimize biases that might be
introduced because of tumor heterogeneity, the study required that
the dominant tumor focus in the peripheral zone of the prostatectomy
specimens be used for molecular marker analysis. The revised Gleason
scoring system (Epstein et al., 2005) was used for pathological
evaluation.
Caseswere selected for immunohistochemistry based on (a) presence
of acinar prostatic adenocarcinoma exclusive of other histologic types;
(b) presence of at least one tumor originating in the peripheral zone of
the prostate; (c) GS of 6 (3 + 3), 7 (3 + 4), or 7(4 + 3); (d) presence
of GG3 and/or GG4 forming distinct clusters; (e) tissue preservation;
and (f) size of at least 0.5 cm in greatest dimension within a section.
Criteria for exclusion were (a) presence of carcinoma of the prostate
other than acinar; (b) absence of adenocarcinoma originating in the
peripheral zone; (c) GS of 8 or above; (d) insufficient tumor in recuts;
and (e) poor tissue preservation. Presence of tertiary GG5 was not a
criterion for exclusion of the case. Particular sections of any given case
that had been decalcified prior to paraffin embedding were excluded.
One block per case that best represented distinct areas of GG3 and/orGG4 was selected and retrieved from the archive. Consecutive blank
sections of the block were prepared on charged slides for immunohisto-
chemistry, and the last of those sections was stained with HE.
Areas of interest were selected under light microscopy on HE
sections obtained prior to and after sections were cut for markers
to check for sufficient tumor through all the stained sections (Eclipse
CiL, Nikon). Five or more GG3 or GG4 glands within an area of
analysis from the largest peripheral zone focus were evaluated per
specimen. Consensual diagnostic criteria were used to identify GG3
and GG4 (fused glands or poorly formed glands). Different GG4
patterns, including fused, poorly formed, and cribriform, were
scored, but only the predominant pattern was included in the analy-
sis. Cribriform was the predominant GG4 pattern in only seven cases
(two in the finasteride arm and five in the placebo arm). A perma-
nent marker was used to map the areas on the slides. Five or more
GG3/GG4 glands within an area of analysis from the dominant
cancers in the peripheral zone were evaluated per specimen. Using
these specimens, we undertook discriminating marker expression
studies to detect seven markers: Ki67, AR, and cleaved caspase 3
(BOND-III automated immunostainer, Leica Biosystems); and estro-
gen receptor β (ERβ), ubiquitin-conjugating enzyme E2C (UBE2C),
3-oxo-5α-steroid 4-dehydrogenase 2 (SRD5A2), and vascular epithelial
growth factor (VEGF) (Dako autostainer, Dako North America). (See
Supplementary Methods S4—Procedure for Derivation and Analysis of
Preselected Molecular Markers.)
Immunohistochemistry study was performed in the Stanford
Alexander Tissue Derivative Laboratory (by EE) of the David H. Koch
Center for Applied Research of Genitourinary Cancers at MD Anderson
Cancer Center. Multitissue controls were used. Incubation was with
primary antibodies Ki-67 (1:100; clone MIB-1, Dako), AR (1:30; clone
AR441, Dako), cleaved caspase 3 (1:200; polyclonal, cell signaling
technology), ERβ (1:15; clone PPG5/10, Dako; positive controls, breast
and endometrial cancers; negative controls, lung and colon), UBE2C
(1:50; clone 9D3, Novus Biologicals; positive control, placenta),
SRD5A2 (1:400; polyclonal, LifeSpan BioScience; positive control, testis;
negative controls, colon and lung), and VEGF (1:1; clone SP28, Abcam;
positive control, tonsil). A 3,3′-diaminobenzidine chromogen was used
on all biomarkers.
TheHEand immunostained slides for Ki-67, AR, cleaved caspase 3, ERβ,
and UBE2C were scanned (Aperio ScanScope XT, Aperio Technologies).
Areas of interest were selected on virtual immunostained slides by a
pathologist (EMLNT) using mapped HE slides as reference (ImageScope,
Aperio Technologies). A nuclear algorithm was used to measure the
percentage of immunoreactive cells (nuclear v9 algorithm, Aperio
Technologies) for Ki-67, AR, ERβ, and UBE2C, and a cytoplasmic
algorithm (Color Deconvolution v9) was used for cleaved caspase
3. Each area of interest produced individual Excel files, including
the percentage of positive cells.
Because of technical limitations, markers with diffuse cytoplasmic
staining (SRD5A2 and VEGF) were manually quantitated. The percent-
age of reactive epithelial cells respective of the total number of carcino-
ma cells of the areawas recorded on a 0–100% scale. Intensity of staining
and the subcellular localization were noted.
2.4.4. Statistical Analysis
The prespecified primary objective was to compare discriminating
molecular marker expression in GG3 areas of the finasteride group
with those of the placebo group, adjusting for GS at prostatectomy.
A predefined grade-associated molecular signature was designed and
analyzed before use in tissue interrogation (Supplementary Methods
S4). Sample size was determined by a power analysis that dictated
having 100 in each group to provide 80% power to detect an effect
size of 0.41 in biomarker expression between the two groups,
at a two-sided significance level of 0.05. Early stopping rules and
inclusion/exclusion criteria were prospectively established, and the
protocol required an interim analysis after the first half of patients
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overwhelmingly positive or negative. Patients remained on the
study until the protocol intervention was completed with prostatec-
tomy. All data were collected at the sites and analyzed centrally. We
used descriptive statistics to summarize patient characteristics by
arm and Fisher's exact test and theWilcoxon rank-sum test to assess
differences between the arms. All testing was two sided, unless
reported otherwise.
We also used the Wilcoxon rank-sum test to assess differences
in molecular markers (four components of the predefined grade-
associated molecular signature [ERβ, UBE2C, VEGF, and SRD5A2]
and three markers [Ki-67, cleaved caspase 3, and AR] added post
hoc to the analysis) between and within the two arms. Ki-67 and
cleaved caspase 3 were studied to assess the effect of finasteride on
proliferation and apoptosis, and AR was studied because it lies
downstream of 5α-reductase, a target of finasteride, and is central
to prostate cancer development and progression. The Wilcoxon
signed-rank test was used to assess the within-arm changes of each
of these markers.
To assess exploratory end points, we fitted a multivariable
logistic regression model with the four biomarkers of the predefined
grade-associated molecular signature, age, and exposure (finasteride
versus placebo) as covariates. Potential interaction effects between
biomarkers and exposure armwere explored. Similar analyses assessed
the effect of AR, considering the potential interaction between AR and
the exposure arm. For analyses of both the predefined and the current
markers, no formal adjustments for multiple comparisons were made
because of the analyses' exploratory nature. All statistical analyses
were performed using SAS 9.3.Fig. 1. Enrollment and subject disposition. Participants were enrolle3. Funding and Nonfinancial Support
This work was supported by the National Cancer Institute, National
Institutes of Health (N01-CN-35159). This work was also supported
in part by National Institutes of Health/National Cancer Institute
award number P30 CA016672 and the Genitourinary Cancers Pro-
gram of the Cancer Center Support Grant shared resources at The
University of Texas MD Anderson Cancer Center. Merck, which pro-
vided finasteride and matching placebo, had no role in designing
the study; collecting, analyzing or interpreting data; or writing the
report.
4. Results
4.1. Study Population
Of 2761 patients screened, 204 were randomized between February
2007 and March 2012, and 183 (89.7%) received treatment and were
evaluable (Fig. 1). The median treatment for both groups was 28 days.
Men assigned to the finasteride arm were younger than those in the
placebo arm (median age, 59 years [range, 45–73] versus 62 years
[range, 48–73]; P=0.005); otherwise, the two armswerewellmatched
(Supplementary Table S1). As measured by pill diary and pill count,
adherence was 97.8%. No participant experienced an adverse event of
greater than grade 2 toxicity (National Cancer Institute, 2006).
Similarly, the two groups providing prostatectomy specimens were
balanced for clinical characteristics except for age (Supplementary
Table S2). The finasteride group was younger than the placebo group
(median age, 58 years [range, 45–73] versus 63 years [range, 48–73];d in the study at four sites from February 2007 to March 2012.
89J. Kim et al. / EBioMedicine 7 (2016) 85–93P = 0.004). One hundred thirty prostatectomy specimens were
available for molecular marker analysis. In the finasteride arm and
placebo arm, there were 67 and 75 GG3 tumor areas and 57 and 61
GG4 tumor areas, respectively.
4.2. Pathologic Outcomes
Pathologic characterization of the prostatectomy specimens showed
no difference between the groups (Table 1), which was also true for the
biomarker study groups (Supplementary Table S3). Patient tumor vol-
ume median values were similar overall (finasteride, 1.0 mL [range,
0–9.3mL]; placebo, 0.8mL [range, 0–10.4mL]; P=0.73), aswere values
for cancer foci in the peripheral zone (finasteride, 0.6 mL [range,
0–9.3mL]; placebo, 0.5mL [range, 0–9mL]; P=0.75) and the transition
zone (finasteride, 0.0 mL [range, 0–6 mL]; placebo, 0.0 mL [range,
0–10.4 mL]; P = 0.84). Likewise, tumor volume median values for the
biomarker subgroup were similar overall (finasteride, 0.9 mL [range,
0.01–7.8 mL]; placebo, 0.8 mL [range, 0.01–5.5 mL]; P = 0.79), as
were values for cancer foci in the peripheral zone (finasteride, 0.6 mL
[range, 0.01–7.8 mL]; placebo, 0.7 mL [range, 0–4.2 mL]; P = 0.40)
and the transition zone (finasteride, 0.03mL [range, 0–5.8mL]; placebo,Table 1
Pathologic characteristics of radical prostatectomy specimens after treatment:
All evaluable patients.
Characteristics Finasteride
(N= 89)
N (%)
Placebo
(N= 94)
N (%)
P
Gleason score
6 12 (13.6) 10 (10.8)
0.84
7 71 (80.7) 78 (83.9)
8 2 (2.3) 1 (1.1)
9 3 (3.4) 4 (4.3)
Gleason grade—specimen (primary)
3 65 (73.9) 75 (80.6)
0.29
4 23 (26.1) 18 (19.4)
Gleason grade—specimen (secondary)
3 31 (35.2) 24 (25.8)
0.374 53 (60.2) 64 (68.8)
5 4 (4.5) 5 (5.4)
Tumor, node, metastasis stage
pT2 73 (82.0) 74 (78.7)
0.81pT3a 11 (12.4) 15 (16.0)
pT3b 5 (5.6) 5 (5.3)
Margin of resection
Positive 17 (19.1) 16 (17.0)
Negative 67 (75.3) 76 (80.9) 0.40
Equivocal 5 (5.6) 2 (2.1)
Lymph node status
pN0 46 (51.7) 43 (45.7)
pN1 2 (2.2) 2 (2.1) 0.79
pNX 41 (46.1) 49 (52.1)
Cancer foci
1 15 (16.9) 11 (11.7)
0.73
2 18 (20.2) 20 (21.3)
3 28 (31.5) 28 (29.8)
4 13 (14.6) 20 (21.3)
≥5 15 (16.8) 15 (15.9)
Zonal origin of tumor foci per radical
prostatectomy specimen
PZ 35 (39.3) 38 (40.4)
0.99
PZ + TZ 49 (55.1) 50 (53.2)
PZ + TZ + CZ 2 (2.2) 2 (2.1)
PZ + CZ 0 (0.0) 1 (1.1)
TZ 3 (3.4) 3 (3.2)
Zonal origin—dominant tumor focus
PZ 67 (75.3) 73 (77.7)
0.73
TZ 22 (24.7) 21 (22.3)
Gleason upgrade between biopsy and
prostatectomy
No 63 (70.8) 70 (74.5)
0.62
Yes 26 (29.2) 24 (25.5)
Abbreviations: PZ, peripheral zone; TZ, transition zone; CZ, central zone.0mL [range, 0–3.6 mL]; P= 0.43). After short-term exposure, no signif-
icant differences were found between the groups in GS upgrading
between biopsy and radical prostatectomy, in tumor volume, or in
number of cancer foci. The important premise of this study was that
there would be nomorphologic changes after brief exposure to finaste-
ride so that molecular changes could be delinked from morphology.
4.3. PSA and Hormone Levels
Before intervention, PSA and serum steroid hormone levels were not
statistically different between groups; after intervention, the finasteride
group had significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL;
P b 0.001) and DHT levels (10 ng/dL versus 27 ng/dL; P b 0.001) and a
significantly higher testosterone level (382 ng/dL versus 327 ng/dL;
P = 0.04) than the placebo group. The percentage change was also
significantly different between the groups (Supplementary Table S4).
Estrone and estradiol levels were similar. The same significant asym-
metric distribution in the posttreatment levels of PSA, testosterone,
and DHT between the groups was observed in the biomarker study
(Supplementary Table S5).
4.4. Molecular Markers
In the areas scanned for markers Ki-67, AR, ERβ, and UBE2C, we
found no significant differences between the two groups in either
tumor grade, and the same was true for individual components. Due
to the heterogeneity of the tumor areas, the correlation in molecular
marker expression between different tumor areas was deemed very
minimal. Box plots were generated to display the distribution of the
area analyzed and molecular biomarkers by treatment group and GG
(see Supplementary Figs. S1 and S2).
The individual components of the predefined grade-associated
molecular signature and Ki-67, AR, and cleaved caspase 3 were com-
pared between and within groups. Because our predefined molecular
signature could not distinguish GG4 fromGG3 tumor areas in the place-
bo arm, we were unable to address the primary objective. However, al-
though no significant difference was found in GG3 tumors between the
groups (median, 75.2% versus 78.3%, P=0.41) (Table 2; Supplementary
Fig. S2A), the level of AR in finasteride-exposed GG4 tumors was signif-
icantly lower than that in placebo group GG4 tumors (median, 63.7%
versus 75.9%, P = 0.04) (Supplementary Fig. S2B). Within the finaste-
ride group, AR expression in GG4 tumor areas was numerically lower
than it was in GG3 tumor areas (median, 63.7% versus 75.2%, P =
0.09) (Table 3; Supplementary Fig. S2C). By comparison, the cleaved
caspase 3 level was significantly higher in GG3 (median, 0.2% versus
0.08%, P = 0.03) and GG4 (median, 0.06% versus 0.04%, P = 0.02) tu-
mors from the finasteride group than in those from the placebo group
(Table 3; Supplementary Figs. 2A and 2B). Within each arm, the cleaved
caspase 3 level was significantly higher in GG3 tumors than in GG4 tu-
mors (finasteride: 0.2% versus 0.06%, P b 0.001; placebo: 0.08% versus
0.04%, P b 0.001) (Table 3; Supplementary Figs. 2C and 2D).
In the post hoc analysis of the predefined grade-associated
molecular signature, the fitted multivariable logistic regression
model suggested no significant association between GG and the
biomarkers. Additionally, no significant interaction was found
between each biomarker and the exposure, and the fitted model
indicated neither significant association with GG nor significant
interaction with exposure. Screening for potential confounders
ruled out the possibility that the age difference between the groups
was responsible for the study's results.
5. Discussion
Our results provide insight into grade-specific effects of 5α-
reductase inhibition in early prostate cancer. AR expression was signif-
icantly lower in the finasteride group than in the placebo group and
Table 2
Comparison of biomarkers between treatment arms: Biomarker subgroup.
Within Gleason grade 3 Within Gleason grade 4
Biomarkers N Mean ± SD Median (range) P N Mean ± SD Median (range) P
VEGF3
Finasteride 37 63.9 ± 36.3 80 (5–100)
0.70
48 63.6 ± 35.5 85 (5–100)
0.45
Placebo 55 63.7 ± 38 90 (0–100) 61 59.8 ± 35.4 70 (0–100)
ERβ
Finasteride 35 18.1 ± 15.6 15.0 (0.03–59.0)
0.38
48 15.0 ± 15.1 8.0 (0–49.6)
0.83
Placebo 55 14.8 ± 14.7 6.6 (0.01–56.3) 62 16.7 ± 18.8 9.5 (0–72.8)
AR
Finasteride 35 69.8 ± 17.3 75.2 (21.5–92.1)
0.41
48 64.3 ± 16.67 63.71 (13.5–92.0)
0.04
Placebo 54 72.4 ± 16.7 78.3 (33.8–97.6) 62 68.6 ± 23.1 75.9 (1.4–96.6)
Ki-67
Finasteride 37 1.6 ± 1.4 1.1 (0.05–5.4)
0.75
48 1.8 ± 1.6 1.3 (0.05–7.2)
0.80
Placebo 54 1.5 ± 1.0 1.3 (0.03–4.5) 62 1.7 ± 1.4 1.4 (0.05–7.3)
SRD5A2
Finasteride 45 72.9 ± 37.0 100 (0–100)
0.57
38 71.8 ± 37.6 95 (0–100)
0.61
Placebo 47 64.7 ± 43.7 90 (0–100) 69 64.9 ± 40.8 90 (0–100)
UBE2C
Finasteride 34 0.5 ± 0.4 0.4 (0–1.5)
0.12
46 0.5 ± 0.4 0.3 (0–1.6)
0.86
Placebo 55 0.5 ± 0.5 0.3 (0–2.4) 62 0.5 ± 0.4 0.3 (0–2.3)
Caspase
Finasteride 38 0.4 ± 0.7 0.2 (0.01–4.1)
0.03
47 0.1 ± 0.1 0.06 (0–0.5)
0.02
Placebo 55 0.2 ± 0.2 0.08 (0–0.8) 61 0.06 ± 0.08 0.04 (0–0.6)
Abbreviations: VEGF, vascular epithelial growth factor; ERβ, estrogen receptor beta; AR, androgen receptor; SRD5A2, 3-oxo-5α-steroid 4-dehydrogenase 2; UBE2C, ubiquitin-conjugating
enzyme E2C.
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Expression of cleaved caspase 3, an indicator of apoptosis, while signif-
icantly higher in the finasteride group than the placebo group in both
GG3 and GG4 areas, was found to be significantly lower in GG4 areas
in both groups. The molecular alterations in AR signaling, an adaptive
response to finasteride, were observed only in the GG4 pattern, evi-
dence of the inherent survival advantage indicated by lower levels of
cleaved caspase 3 in GG4 than in GG3 tumor areas in both groups.
This type of difference in cell proliferation was also observed in a
study by Kosaka et al. (2014), who found that 5α-reductase inhibitors
(5ARIs) reduced an indicator of cell proliferation—CDC6 mRNA—in the
androgen-dependent LNCaP cell line but saw the proliferation marker
increase in androgen-independent lines C4-2 and C4-2AT6, the last a
castration-resistant prostate cancer. Interestingly, they found theTable 3
Comparison of biomarkers between GG3 and GG4: Biomarker subgroup.
Within finasteride arm
Biomarker N Mean ± SD Median (range) P
VEGF
GG3 37 63.9 ± 36.3 80 (5–100)
0.84
GG4 48 63.7 ± 35.5 85 (5–100)
ERβ
GG3 35 18.1 ± 15.6 15.0 (0.03–58.9)
0.36
GG4 48 15.0 ± 15.1 8.0 (0–49.56)
AR
GG3 35 69.8 ± 17.3 75.2 (21.5–92.1)
0.09
GG4 48 64.3 ± 16.7 63.7 (13.5–92.0)
Ki-67
GG3 37 1.6 ± 1.4 1.1 (0.05–5.4)
0.46
GG4 48 1.8 ± 1.6 1.3 (0.05–7.2)
SRD5A2
GG3 45 72.9 ± 37.0 100 (0–100)
0.88
GG4 38 71.8 ± 37.6 95 (0–100)
UBE2C
GG3 34 0.5 ± 0.4 0.4 (0–1.5)
0.18
GG4 46 0.5 ± 0.4 0.3 (0–1.6)
Caspase
GG3 38 0.4 ± 0.7 0.2 (0.01–4.1)
b0.0
GG4 47 0.1 ± 0.1 0.06 (0–0.5)
Abbreviations: VEGF, vascular epithelial growth factor; GG, Gleason grade; ERβ, estrogen rece
ubiquitin-conjugating enzyme E2C.reverse effect with DHT. Kosaka and colleagues concluded that 5ARIs
might help accelerate adaptation to aggressive phenotypes in some
prostate cancer types.
Finally, our finding of lower AR expression in GG4 tumor areas after
short-termfinasteride exposure is in linewith an emerging concept that
reduced androgens in prostate tissues may over time lead to derepres-
sion of AR expression,which in turn deregulates AR function and down-
stream derepression of specific AR target genes normally repressed by
androgens (Cai et al., 2011). These gene activities may lead to stochastic
activation of oncogenic signaling that promotes the development of
aggressive prostate cancer.
Molecular modulations we detected suggest temporal dependence
and on-target effects of finasteride are grade dependent, which may
account for previously reported selective suppression by finasteride ofWithin placebo arm
N Mean ± SD Median (range) P
55 63.7 ± 38 90 (0–100)
0.32
61 59.7 ± 35.4 70 (0–100)
55 14.8 ± 14.7 6.6 (0–56.3)
0.83
62 16.7 ± 18.8 9.5 (0–72.8)
54 72.4 ± 16.7 78.3 (33.77–97.6)
0.77
62 68.6 ± 23.1 75.9 (1.39–96.6)
54 1.5 ± 1.0 1.3 (0.03–4.5)
0.87
62 1.7 ± 1.4 1.4 (0.05–7.3)
47 64.7 ± 43.7 90 (0–100)
0.91
69 64.9 ± 40.8 90 (0–100)
55 0.5 ± 0.5 0.3 (0–2.4)
0.90
62 0.5 ± 0.4 0.3 (0–2.3)
01
55 0.2 ± 0.2 0.08 (0–0.8)
b0.001
61 0.06 ± 0.08 0.04 (0–0.6)
ptor beta; AR, androgen receptor; SRD5A2, 3-oxo-5α-steroid 4-dehydrogenase 2; UBE2C,
Fig. 2.Comparisons offinasteride-exposedGleason grade 3 and 4 tumors. Pathology studies of finasteride-exposed groupGleason grade (GG)3 component are comparedwith those of the
GG4 component. Hematoxylin and eosin stains of GG3 and GG4 tumor areas (A and B, respectively) from two different cases and corresponding parallel illustrations of
immunohistochemistry for androgen receptor (C and D, respectively) are shown. Black arrows indicate nonneoplastic glands.
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not detectedmay include the discrepancy between the source of tissues
used to define the signature and the early cancer cases in the study.
Specimens used to define the signature were derived from more
extreme samples of prostate cancer (GG3 specimens from GS6 prostate
cancer and GG4 specimens from GS8 or GS9 prostate cancers, including
all GG4 patterns) than the generally low- or intermediate-risk cancers
present in the study population. Therefore, in subsequent studies,
investigators may need to match more closely entry criteria of men
who are subjects and characteristics of men fromwhom tissue samples
are taken.
The development of the prespecified molecular signature had been
based on the hypothesis that if finasteride caused high-grade cancer,
a high-grade molecular signature would be detectable with greater
frequency after exposure to finasteride than after exposure to placebo.
This was based on the presumption that disease progression in
early stage prostate cancer occurred in a step-wise fashion (e.g., GG3
tumors would precede GG4 tumors), but progression theories remain
controversial.
Wang et al. (2009), for example, have shown inmice that castration-
resistant Nkx3-1 (CARN) cells—rare luminal epithelial stem cells that
survive androgen withdrawal—can give rise to basal, luminal, and
neuroendocrine cells after restoration of androgen. Others have shown
these cells also regenerate ducts and self-renew (Leong et al., 2008).
By deleting the tumor-suppressing gene Pten in these cells, Wang
et al. further demonstrated that high-grade prostatic intraepithelial
neoplasia, and carcinoma rapidly formed in the Pten-free system, with
CARN cells serving as cells of origin after androgen-mediated renewal.
It wasn't that we expected, based on the long-standing presumption
of step-wise progression, that finasteride would be found responsiblefor the high-grade disease detected by others; in fact, it was an effort
to examine the nexus of transition and begin to characterize the
molecular processes.
Our study's design provided an ideal opportunity to back-validate
markers of apoptosis (e.g., cleaved caspase 3) and cellular prolifera-
tion (e.g., Ki-67), which are commonly used in this class of chemo-
preventive agents as surrogates for chemoprevention efficacy in
short-term, phase II clinical trials in prostate cancer and other
cancers (Parnes et al., 2013). After short-term exposure to finasteride,
expression of the apoptotic factor cleaved caspase 3 in GG3 and GG4
tumor areas was significantly increased, demonstrating, as shown in
the PCPT, preventive efficacy. Additionally, within both arms, levels of
cleaved caspase 3 were significantly lower in GG4 tumors than in GG3
tumors. Ananthanarayanan et al. (2006) and Ummanni et al. (2010)
independently found that, compared with levels of activated caspase 3
in normal prostate epithelium, levels of activated caspase 3 in untreated
prostate cancer from radical prostatectomy specimenswere significant-
ly lower. Evidence that Ki-67 was modulated by finasteride was not
detected during the study.
Findings conflict regarding the influence of 5ARIs on apoptosis. Bass
et al. (2009) showed no effect on caspase 3 in a randomized, placebo-
controlled, presurgical 30-day finasteride intervention in localized
prostate cancer (N = 22 in each arm). However, results of two
dutasteride studies, both using terminal deoxynucleotidyl transferase
dUTP nicked-end labeling, indicated effects, but findings were contra-
dictory. Andriole et al. (2004), in a double-blind, randomized placebo-
controlled trial, reported higher apoptosis levels in 46menwith clinical-
ly organ-confined prostate cancer treated with dutasteride or placebo
for 6–10 weeks before prostatectomy. In contrast, Gleave et al. (2006)
reported a significant decrease in apoptosis when dutasteride was
92 J. Kim et al. / EBioMedicine 7 (2016) 85–93compared with placebo for four months before prostatectomy. This
further supports the notion that the molecular effects of 5ARIs depend
on exposure duration.
In contrast to our results, findings of Thomas et al. (2008) in untreat-
ed tumors indicate expression of SRD5A2, the target of finasteride,
is higher in high-grade than in low-grade localized disease. Their earlier
work had indicated in part that SRD5A2 expression rose as prostate
cancer progressed (Thomas et al., 2005). Differences between study
populations may explain the discordance, inasmuch as Thomas
et al. examined GG3, GG4, and GG5 components from cancer overall
(GSs of 5–8, GSs of 7–9, and GSs of 8–10, respectively), whereas
expression we studied was in tumor foci with a narrow range of
Gleason scores.
Although we detected no change in the estrone or estradiol ligands
of ER, estrogen has been shown by others to be important in prostate
carcinogenesis and progression (Weihua et al., 2002). In early prostate
cancer in the context of prostate cancer prevention with finasteride
(Mak et al., 2010), 3β-adiol, a metabolite of DHT and a ligand of ERβ,
may be important in cross-talk between AR and ER signaling. Further-
more, the biological significance of ER signaling in persistent low- and
high-grade cancers warrants further investigation.
Limitations of this study and its findings include the brief period
over which the study was conducted and the focus on tumors of the
peripheral zone. We did not observe an interaction between finasteride
and ERβ or between finasteride and SRD5A2 in comparisons by group
or GG; however, it may be that molecular adaptation by tumors to
finasteride exposure may occur over a longer period of time than was
assessed in this investigation. Likewise, Ki-67's failure to be modulated
byfinasteride, a drug proven to reduce prostate cancer risk, underscores
the time limitation in this trial. In addition, it is a limitation that our
results are based on tumors of peripheral zone origin and that the GG
patterns evaluated primarily included poorly formed and fused glands.
Therefore, it remains unknown if our results apply to tumors of transi-
tion zone origin or other GG4 patterns.
Ours is one of few studies in early prostate cancer to consider the
time it takes for response to therapy to be reflected in gene expression,
but it has been studied inmore advanced prostate cancers. Although AR
expression four months following androgen deprivation therapy in a
neoadjuvant setting before radical prostatectomy was not increased in
hormone-naive high-grade cancers (Efstathiou et al., 2013), an increase
in expression and a commensurate AR gene copy number increase have
been frequently observed in castration-resistant prostate cancer (Scher
et al., 2004), and expression further increased after only eight weeks of
abiraterone (Efstathiou et al., 2012). Our findings emphasize the need to
understand the temporal relationships offinasteride-inducedmolecular
changes and their biological and clinical implications.
Overall, finasteride's differential modulation of AR in GG3 versus
GG4 areas of tumor suggests grade-associated differences in AR signal-
ing in early prostate cancer. The heterogeneity of AR signaling networks
has been recognized for a long time. In work with cell lines (Li et al.,
2011), we found dramatic variability characterized AR signaling:
complicated self-regulation controlled the central axis of AR signaling,
5α-reductase expression varied across cell lines, each cell line varied
in response to androgen, androgen controlled 5α-reductase transcrip-
tion through the AR pathway, and expression of each of the three
5α-reductase enzymes was cell-type specific.
Confining the study to the largest focus of the peripheral zone,
thereby limiting any bias introduced by the tumor heterogeneity
inherent in the multifocal and multizonal nature of prostate cancer,
reinforces confidence in the findings. Perhaps high-grade tumors
are more sensitive than low-grade tumors to the disequilibrium of
testosterone and DHT caused by finasteride or dutasteride, and, as a
consequence, AR expression paradoxically decreases as a short-term
adaptation. A corollary may be that low-grade tumors are more depen-
dent than high-grade tumors on DHT. If so, this may be the mechanism
whereby finasteride and dutasteride reduced the likelihood of findinglow-grade tumors on biopsy in other trials (Thompson et al., 2003;
Andriole et al., 2010).
In summary, this randomized, controlled trial, whichwas undertaken
to improve understanding of molecular modulations associated with
high-grade disease found in finasteride-exposed clinically organ-
confined prostate cancer, identified grade-specific AR molecular
effects that refine notions of appropriate use of 5ARIs and suggest
specialized applications. Confirmation of these findings may provide
a dynamic test enabling prospective identification of finasteride-
responsive cancers or lead to predictive markers for allocating ther-
apies or predicting risk of progression.
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